Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination
Phase 4
Completed
- Conditions
- GlaucomaOcular Hypertension
- Registration Number
- NCT00941096
- Lead Sponsor
- Larissa University Hospital
- Brief Summary
The purpose of this study is to examine the ocular hypotensive effect of Bimatoprost and the potential additional effect of the Bimatoprost/Timolol fixed combination in eyes with ocular hypertension, primary open angle glaucoma or exfoliation glaucoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Primary open angle glaucoma
- Exfoliation glaucoma
- Ocular hypertension
Exclusion Criteria
- Younger than 18 years old
- Inability to understand and/or follow study requirements
- Women of childbearing potential not using reliable birth control, pregnant or lactating women
- History of chronic obstructive pulmonary disease, heart failure, 2nd or 3rd AV block
- Anticipated modification of treatment for systemic hypertension during the study period
- History of ocular herpes, corneal scarring, conventional or laser surgery or macular pathology
- History of allergy, poor tolerability or poor response to study medication
- Best corrected visual acuity less than 0.4
- Significant visual field defect (MD<15.0 dB)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Mean diurnal intraocular pressure Five weeks on each medication
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Bimatoprost's intraocular pressure reduction in primary open angle glaucoma?
How does the Bimatoprost/Timolol fixed combination compare to monotherapy in managing ocular hypertension?
Are there specific biomarkers that predict enhanced response to Bimatoprost/Timolol in exfoliation glaucoma patients?
What adverse events are associated with Bimatoprost/Timolol combination therapy in Phase 4 trials for glaucoma?
What are the current drug development trends in fixed combination therapies for primary open angle glaucoma and exfoliation glaucoma?
Trial Locations
- Locations (1)
University Eye Clinic
🇬🇷Larissa, Thessaly, Greece
University Eye Clinic🇬🇷Larissa, Thessaly, Greece